Roche suffers a fresh blow as India’s Supreme Court allows generic sales of its pricey rare disease drug

In a recent case that sparked debate between profits and patients, the Supreme Court of India made a significant decision to dismiss a petition filed by Roche, a pharmaceutical company. The petition aimed to prevent a generic drug maker, Natco Pharma, from selling a lower-cost version of a rare disease medication called Evrysdi.

The lower court had previously ruled in favor of Natco Pharma, allowing them to sell Evrysdi for a mere $179 per bottle. In stark comparison, Roche priced the same drug at a staggering $6,982 per bottle. Evrysdi is primarily used to treat spinal muscular atrophy, a genetic disorder that causes muscle weakness and wasting, with severe cases potentially leading to death by age 2 if left untreated.

The decision comes at a crucial time as more than 5,000 individuals in India are currently living with spinal muscular atrophy, and approximately 3,200 children are born with the condition each year. Despite the urgent need for treatment, only a small fraction of patients had access to the expensive drug, with fewer than 170 people receiving it annually. The annual cost for an adult patient amounts to $81,000, making it unaffordable for many. Although a patient assistance program exists, it is only accessible to a limited number of individuals, as described by the Delhi High Court as “minuscule.”

The case underscores the ethical dilemma faced by pharmaceutical companies in balancing profits with patient access to life-saving medications. The Supreme Court’s decision to allow Natco Pharma to sell a more affordable version of Evrysdi is a step towards ensuring greater access to treatment for individuals affected by rare diseases. This ruling not only addresses the financial burden faced by patients but also highlights the importance of prioritizing public health interests over corporate profits.

It is crucial for pharmaceutical companies to consider the affordability and accessibility of medications, especially for rare diseases with limited treatment options. The Supreme Court’s decision sets a precedent for promoting equitable healthcare access and underscores the need for more affordable alternatives in the pharmaceutical industry.